Biohaven reports second quarter 2023 financial results and recent business developments

Cash, cash equivalents, and marketable securities totaled $349.0 million as of june 30, 2023 announced positive interim data from bhv-7000 eeg biomarker study demonstrating evidence of central nervous system (cns) target engagement, confirming previously reported preclinical and clinical data, and highlighting the paradigm-changing potential of bhv-7000 in the treatment of epilepsy and mood disorders brain penetrant tyk2/jak1 inhibitor, bhv-8000, advanced into phase 1 with projected therapeutic concentrations achieved and well-tolerated profile observed to date biohaven anticipates initiating a phase 2 clinical trial in parkinson's disease and potentially other neuroinflammatory diseases in 2024 advanced targeted extracellular protein degradation platform with potential to support numerous clinical candidates across a broad range of high unmet need indications investigational new drug (ind) submission for pan-igg degrader, bhv-1300, on track for the second half of 2023 with potential to treat multiple immune-mediated diseases ind submission with iga degrader for iga nephropathy expected in the first half of 2024 orphan drug designation (odd) granted by the european commission for taldefgrobep alfa a novel anti-myostatin adnectin, for the treatment of spinal muscular atrophy (sma) taldefgrobep previously received fast-track and odd from the fda taldefgrobep phase 3 sma trial expected to complete enrollment in the second half of 2023 type a meeting planned with fda regarding troriluzole program in spinocerebellar ataxia type 3 (sca3) and enrollment in phase 3 obsessive compulsive disorder (ocd) trial expected to complete at end of 2023 new haven, conn. , july 31, 2023 /prnewswire/ -- biohaven ltd.
BHVN Ratings Summary
BHVN Quant Ranking